Nasus Pharma Announces Abstracts Accepted for Presentation at ACAAI 2026
Key Highlights
- ➤NS002 abstracts accepted for oral and three poster presentations at ACAAI 2026
- ➤Oral presentation covers enhanced absorption after a single dose in adults with allergic rhinitis
- ➤Poster data address NS002 absorption under severe nasal congestion
- ➤Company survey data assess speed of onset as an anaphylaxis treatment priority
Expert Statements
Brendan O’Grady, Chief Executive Officer of Nasus Pharma
“Speed of Onset as the Clinical Priority in Anaphylaxis Treatment: New Allergist Survey Data”
TEL AVIV, Israel, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Nasus Pharma Ltd. (NYSE: NSRX) (“Nasus Pharma” or the “Company”), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced that abstracts supporting NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, have been accepted for presentation at the upcoming the American College of Allergy, Asthma & Immunology (“ACAAI”) 2026 Annual Scientific Meeting, to be held in Phoenix, AZ November 12-16, 2026.
The abstract Enhanced Absorption of Intranasal Powder Epinephrine (FMXIN002) after Single Dose in Adults with Allergic Rhinitis (8032) was selected for oral presentation in the Distinguish Industry and Late Breaking Abstracts session. The abstract will be presented Saturday, November 14, by Dr. Michael Blaiss.
Get started
Create a free account to read the full story.